Proteolytic cleavages of MET: the divide-and-conquer strategy of a receptor tyrosine kinase

키워드

참고문헌 (90)

1. Birchmeier C, "Met, metastasis, motility and more", Nat Rev Mol Cell Biol, 4, pp.915~925 (2003)
2. Bladt F, "Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud", Nature, 376, pp.768~771 (1995)
3. Schmidt C, "Scatter factor", hepatocyte growth factor is essential for liver development, 1995, pp.373, 699~702
4. Uehara Y, "Placental defect and embryonic lethality in mice lacking hepatocyte growth factor", scatter factor, 1995, pp.373, 702~705
5. Maina F, "Met receptor signaling is required for sensory nerve development and HGF promotes axonal growth and survival of sensory neurons", Genes Dev, 11, pp.3341~3350 (1997)
6. Chmielowiec J, "c-Met is essential for wound healing in the skin", J Cell Biol, 177, pp.151~162 (2007)
7. Borowiak M, "Met provides essential signals for liver regeneration", Proc Natl Acad Sci U S A, 101, pp.10608~10613 (2004)
8. Huh CG, "Hepatocyte growth factor", c-met signaling pathway is required for efficient liver regeneration and repair, 2004, pp.101, 4477~4482
9. Schiering N, "Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a", Proc Natl Acad Sci U S A, 100, pp.12654~12659 (2003)
10. Longati P, "Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET protooncogene(HGF receptor)", Oncogene, 9, pp.49~57 (1994)
11. Ponzetto C, "A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor", scatter factor receptor family, 1994, pp.77, 261~271
12. Maina F, "Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development", Cell, 87, pp.531~542 (1996)
13. Peschard P, "Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein", Mol Cell, 8, pp.995~1004 (2001)
14. Hashigasako A, "Bi-directional regulation of Ser-985 phosphorylation of c-met via protein kinase C and protein phosphatase 2A involves c-Met activation and cellular responsiveness to hepatocyte growth factor", J Biol Chem, 279, pp.26445~26452 (2004)
15. Duplaquet L, "The multiple paths towards MET receptor addiction in cancer", Oncogene, 37, pp.3200~3215 (2018)
16. Olivero M, "Overexpression and activation of hepatocyte growth factor", scatter factor in human non-small-cell lung carcinomas, 1996, pp.74, 1862~1868
17. Ichimura E, "Expression of c-met", HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance, 1996, pp.87, 1063~1069
18. Wislez M, "Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma : role in tumor progression and death", Cancer Res, 63, pp.1405~1412 (2003)
19. Park S, "High MET copy number and MET overexpression : poor outcome in non-small cell lung cancer patients", Histol Histopathol, 27, pp.197~207 (2012)
20. Koochekpour S, "Met and hepatocyte growth factor", scatter factor expression in human gliomas, 1997, pp.57, 5391~5398
21. Ferracini R, "The Met", HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit, 1995, pp.10, 739~749
22. Tuck AB, "Coexpression of hepatocyte growth factor and receptor(Met)in human breast carcinoma", Am J Pathol, 148, pp.225~232 (1996)
23. Ponzetto C, "c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase", Oncogene, 6, pp.553~559 (1991)
24. Watermann I, "Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?", Diagn Pathol, 10, pp.130~ (2015)
25. Yang Y, "MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer", Gastric Cancer, 19, pp.778~788 (2016)
26. Sattler M, "The role of the c-Met pathway in lung cancer and the potential for targeted therapy", Ther Adv Med Oncol, 3, pp.171~184 (2011)
27. Krishnaswamy S, "Ethnic differences and functional analysis of MET mutations in lung cancer", Clin Cancer Res, 15, pp.5714~5723 (2009)
28. Baldacci S, "Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors", Oncotarget, 8, pp.105103~105114 (2017)
29. Prat M, "C-terminal truncated forms of Met, the hepatocyte growth factor receptor", Mol Cell Biol, 11, pp.5954~5962 (1991)
30. Galvani AP, "Suramin modulates cellular levels of hepatocyte growth factor receptor by inducing shedding of a soluble form", Biochem Pharmacol, 50, pp.959~966 (1995)
31. Jeffers M, "Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway", Mol Cell Biol, 17, pp.799~808 (1997)
32. Kopitz C, "Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling", Cancer Res, 67, pp.8615~8623 (2007)
33. Schelter F, "A disintegrin and metalloproteinase-10(ADAM-10)mediates DN30antibody-induced shedding of the met surface receptor", J Biol Chem, 285, pp.26335~26340 (2010)
34. Wajih N, "Vascular origin of a soluble truncated form of the hepatocyte growth factor receptor(c-met)", Circ Res, 90, pp.46~52 (2002)
35. Foveau B, "Downregulation of the Met Receptor Tyrosine Kinase by Presenilindependent Regulated Intramembrane Proteolysis", Mol Biol Cell, 20, pp.2494~2506 (2009)
36. Ancot F, "Shedding-Generated Met Receptor Fragments can be Routed to Either the Proteasomal or the Lysosomal Degradation Pathway", Traffic, 13, pp.1261~1272 (2012)
37. Miller MA, "ADAM-10 and-17 regulate endometriotic cell migration via concerted ligand and receptor shedding feedback on kinase signaling", Proc Natl Acad Sci U S A, 110, pp.E2074~2083 (2013)
38. Trusolino L, "MET signalling : principles and functions in development, organ regeneration and cancer", Nat Rev Mol Cell Biol, 11, pp.834~848 (2010)
39. Copin MC, "High-MET status in non-small cell lung tumors correlates with receptor phosphorylation but not with the serum level of soluble form", Lung Cancer, 101, pp.59~67 (2016)
40. McNeil BK, "Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder", J Transl Med, 12, pp.199~ (2014)
41. Michieli P, "Targeting the tumor and its microenvironment by a dual-function decoy Met receptor", Cancer Cell, 6, pp.61~73 (2004)
42. Tulasne D, "Proapoptotic function of the MET tyrosine kinase receptor through caspase cleavage", Mol Cell Biol, 24, pp.10328~10339 (2004)
43. Lefebvre J, "Caspasegenerated fragment of the Met receptor favors apoptosis via the intrinsic pathway independently of its tyrosine kinase activity", Cell Death Dis, 4, pp.e871~ (2013)
44. Mebratu YA, "Bik reduces hyperplastic cells by increasing Bak and activating DAPk1 to juxtapose ER and mitochondria", Nat Commun, 8, pp.803~ (2017)
45. Foveau B, "Amplification of apoptosis through sequential caspase cleavage of the MET tyrosine kinase receptor", Cell Death Differ, 14, pp.752~764 (2007)
46. Ma J, "A novel death defying domain in met entraps the active site of caspase-3 and blocks apoptosis in hepatocytes", Hepatology, 59, pp.2010~2021 (2013)
47. Furlan A, "How does met regulate the survival", apoptosis balance?, 2013, pp.60, 1108~1109
48. Peschard P, "A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl", Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation, 2004, pp.279, 29565~29571
49. Deheuninck J, "Phosphorylation of the MET receptor on juxtamembrane tyrosine residue 1001 inhibits its caspase-dependent cleavage", Cell Signal, 21, pp.1455~1463 (2009)
50. Deheuninck J, "Caspase cleavage of the MET receptor generates an HGF interfering fragment", Biochem Biophys Res Commun, 367, pp.573~577 (2008)
51. Bredesen DE, "Receptors that mediate cellular dependence", Cell Death Differ, 12, pp.1031~1043 (2005)
52. Negulescu AM, "Dependence receptors-the dark side awakens", FEBS J, 285, pp.3909~3924 (2018)
53. Ichim G, "The Dependence Receptor TrkC Triggers Mitochondria-Dependent Apoptosis upon Cobra-1 Recruitment", Mol Cell, 51, pp.632~646 (2013)
54. Menard M, "Hey1-and p53-dependent TrkC proapoptotic activity controls neuroblastoma growth", PLoS Biol, 16, pp.e2002912~ (2018)
55. Halestrap AP, "A pore way to die : the role of mitochondria in reperfusion injury and cardioprotection", Biochem Soc Trans, 38, pp.841~860 (2010)
56. Francis RJ, "Ca2+activation of cytosolic calpain induces the transition from apoptosis to necrosis in neutrophils with externalized phosphatidylserine", J Leukoc Biol, 93, pp.95~100 (2013)
57. Yun B, "Serine hydrolase inhibitors block necrotic cell death by preventing calcium overload of the mitochondria and permeability transition pore formation", J Biol Chem, 289, pp.1491~1504 (2014)
58. Montagne R, "Necrosisand apoptosis-related Met cleavages have divergent functional consequences", Cell Death Dis, 6, pp.e1769~ (2015)
59. Billger M, "Proteolysis of tubulin and microtubule-associated proteins 1 and 2 by calpain I and II. Difference in sensitivity of assembled and disassembled microtubules", Cell Calcium, 9, pp.33~44 (1988)
60. Czogalla A, "Spectrin and calpain : a 'target' and a 'sniper' in the pathology of neuronal cells", Cell Mol Life Sci, 62, pp.1913~1924 (2005)
61. Kelly BL, "Beta-amyloidinduced dynamin 1 depletion in hippocampal neurons. A potential mechanism for early cognitive decline in Alzheimer disease", J Biol Chem, 280, pp.31746~31753 (2005)
62. Cortot AB, "Exon 14 deleted MET receptor as a new biomarker and target in cancers", J Natl Cancer Inst, 109 (2017)
63. Lee JH, "A novel germ line juxtamembrane Met mutation in human gastric cancer", Oncogene, 19, pp.4947~4953 (2009)
64. Ma PC, "c-MET mutational analysis in small cell lung cancer : novel juxtamembrane domain mutations regulating cytoskeletal functions", Cancer Res, 63, pp.6272~6281 (2003)
65. Tyner JW, "MET receptor sequence variants R970C and T992I lack transforming capacity", Cancer Res, 70, pp.6233~6237 (2010)
66. Shieh JM, "Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis", Int J Med Sci, 10, pp.988~994 (2013)
67. Boland JM, "MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma : molecular analysis of 25 ALK-positive cases", J Thorac Oncol, 8, pp.574~581 (2013)
68. Zaffaroni D, "Met proto-oncogene juxtamembrane rare variations in mouse and humans : differential effects of Arg and Cys alleles on mouse lung tumorigenesis", Oncogene, 24, pp.1084~1090 (2005)
69. Montagne R, "MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering", Oncotarget, 8, pp.11268~11283 (2017)
70. Merilahti JAM, "Gamma-secretasedependent signaling of receptor tyrosine kinases", Oncogene, 38, pp.151~163 (2019)
71. Matteucci E, "Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells", Carcinogenesis, 30, pp.937~945 (2009)
72. CHAUDHARYSHUBHASHCHANDRA, "A putative pH-dependent nuclear localization signal in the juxtamembrane region of c-Met", Experimental and Molecular Medicine, 46, pp.1~13 (2014), 생화학분자생물학회
73. Tauszig-Delamasure S, "The TrkC receptor induces apoptosis when the dependence receptor notion meets the neurotrophin paradigm", Proc Natl Acad Sci U S A, 104, pp.13361~13366 (2007)
74. Bordeaux MC, "The RET proto-oncogene induces apoptosis : a novel mechanism for Hirschsprung disease", EMBO J, 19, pp.4056~4063 (2000)
75. Wang H, "The Proto-oncogene c-Kit Inhibits Tumor Growth by Behaving as a Dependence Receptor", Mol Cell, 72, pp.413~425 (2018)[DOI]
76. Genevois AL, "Dependence receptor TrkC is a putative colon cancer tumor suppressor", Proc Natl Acad Sci U S A, 110, pp.3017~3022 (2013)
77. Luo Y, "NTRK3 is a potential tumor suppressor gene commonly inactivated by epigenetic mechanisms in colorectal cancer", PLoS Genet, 9, pp.e1003552~ (2013)
78. De Oliveira AT, "MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality", Anticancer Res, 29, pp.4807~4811 (2009)
79. Petrelli A, "Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity", Proc Natl Acad Sci U S A, 103, pp.5090~5095 (2006)
80. Pacchiana G, "Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody", J Biol Chem, 285, pp.36149~36157 (2010)
81. Cignetto S, "Dual Constant Domain-Fab : A novel strategy to improve half-life and potency of a Met therapeutic antibody", Mol Oncol, 10, pp.938~948 (2016)
82. Vigna E, "Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30", Mol Oncol, 9, pp.1760~1772 (2015)
83. Vigna E, "Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor", J Mol Med (Berl), 92, pp.65~76 (2014)
84. Basilico C, "Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy"strategy", Int J Cancer (2018)
85. Perk LR, "Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30", Eur J Nucl Med Mol Imaging, 35, pp.1857~1867 (2008)
86. Athauda G, "c-Met ectodomain shedding rate correlates with malignant potential", Clin Cancer Res, 12(14 Pt 1), pp.4154~4162 (2006)
87. Fu L, "Shedding of c-Met ectodomain correlates with c-Met expression in non-small cell lung cancer", Biomarkers, 18, pp.126~135 (2013)
88. Lv H, "Soluble c-Met is a reliable and sensitive marker to detect c-Met expression level in lung cancer", Biomed Res Int, 2015, pp.626578~ (2015)
89. Engelman JA, "MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling", Science, 316, pp.1039~1043 (2007)
90. Siebel C, "Notch Signaling in Development, Tissue Homeostasis, and Disease", Physiol Rev, 97, pp.1235~1294 (2017)